keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell lung cancer side effects

keyword
https://www.readbyqxmd.com/read/28640251/inhibition-of-cancer-growth-in-vitro-and-in-vivo-by-a-novel-ros-modulating-agent-with-ability-to-eliminate-stem-like-cancer-cells
#1
Jiankang Wang, Bingling Luo, Xiaobing Li, Wenhua Lu, Jing Yang, Yumin Hu, Peng Huang, Shijun Wen
Reactive oxygen species (ROS) have a crucial role in cell signaling and cellular functions. Mounting evidences suggest that abnormal increase of ROS is often observed in cancer cells and that this biochemical feature can be exploited for selective killing of the malignant cells. A naturally occurring compound phenethyl isothiocyanate (PEITC) has been shown to have promising anticancer activity by modulating intracellular ROS. Here we report a novel synthetic analog of PEITC with superior in vitro and in vivo antitumor effects...
June 22, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28625638/development-of-psoriatic-arthritis-during-nivolumab-therapy-for-metastatic-non-small-cell-lung-cancer-clinical-outcome-analysis-and-review-of-the-literature
#2
Juan Ruiz-Bañobre, Eva Pérez-Pampín, Jorge García-González, Antonio Gómez-Caamaño, Francisco Javier Barón-Duarte, Rafael López-López, Francisca Vázquez-Rivera
Lung cancer is the leading cause of cancer-related death worldwide. The most common type, non-small cell lung cancer (NSCLC), is further divided into two main types, squamous cell and non-squamous cell (which includes adenocarcinoma). Nivolumab, a fully human IgG4 programmed death-1 immune checkpoint inhibitor antibody, has shown not only an overall survival advantage when compared to docetaxel, but also a relatively good side-effect profile among patients with previously treated advanced squamous and non-squamous NSCLC...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28618947/treatment-outcome-comparisons-between-exons-19-and-21-egfr-mutations-for-non-small-cell-lung-cancer-patients-with-malignant-pleural-effusion-after-first-line-and-second-line-tyrosine-kinase-inhibitors
#3
Zhen Zheng, Deyao Xie, Huafang Su, Baochai Lin, Lihao Zhao, Xia Deng, Hanbin Chen, Shaoran Fei, Xiance Jin, Congying Xie
Recent studies demonstrated a significantly increased frequency of epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) patients with malignant pleural effusions (MPEs). The purpose of this study is to investigate the effect of first-line and second-line EGFR-tyrosine kinase inhibitors (TKIs) in the treatment of NSCLC with MPEs harboring exon 19 deletion and L858R mutation. From 2010 to 2015, 203 NSCLC patients with MPEs harboring EGFR mutation treated with EGFR-TKIs were reviewed...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28598823/preclinical-data-on-the-combination-of-cisplatin-and-anti-cd70-therapy-in-non-small-cell-lung-cancer-as-an-excellent-match-in-the-era-of-combination-therapy
#4
Julie Jacobs, Vanessa Deschoolmeester, Christian Rolfo, Karen Zwaenepoel, Jolien Van den Bossche, Christophe Deben, Karen Silence, Hans de Haard, Christophe Hermans, Sylvie Rottey, Christel Vangestel, Filip Lardon, Evelien Smits, Patrick Pauwels
In contrast to the negligible expression of the immunomodulating protein CD70 in normal tissue, we have demonstrated constitutive overexpression of CD70 on tumor cells in a subset of primary non-small cell lung cancer (NSCLC) biopsies. This can be exploited by CD70-targeting antibody-dependent cellular cytotoxicity (ADCC)-inducing antibodies. Early clinical trials of these antibodies have already shown promising results in CD70-positive malignancies.In this study, we explored the potential of cisplatin to induce CD70 expression in NSCLC...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28596092/stereotactic-body-radiation-therapy-for-early-stage-non-small-cell-lung-cancer-executive-summary-of-an-astro-evidence-based-guideline
#5
Gregory M M Videtic, Jessica Donington, Meredith Giuliani, John Heinzerling, Tomer Z Karas, Chris R Kelsey, Brian E Lally, Karen Latzka, Simon S Lo, Drew Moghanaki, Benjamin Movsas, Andreas Rimner, Michael Roach, George Rodrigues, Shervin M Shirvani, Charles B Simone, Robert Timmerman, Megan E Daly
PURPOSE: This guideline presents evidence-based recommendations for stereotactic body radiation therapy (SBRT) in challenging clinical scenarios in early-stage non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: The American Society for Radiation Oncology convened a task force to perform a systematic literature review on 4 key questions addressing: (1) application of SBRT to operable patients; (2) appropriate use of SBRT in tumors that are centrally located, large, multifocal, or unbiopsied; (3) individual tailoring of SBRT in "high-risk" clinical scenarios; and (4) SBRT as salvage therapy after recurrence...
June 5, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28587258/combination-of-near-infrared-light-activated-photodynamic-therapy-mediated-by-indocyanine-green-with-etoposide-to-treat-non-small-cell-lung-cancer
#6
Ting Luo, Qinrong Zhang, Qing-Bin Lu
Indocyanine green (ICG) has been reported as a potential near-infrared (NIR) photosensitizer for photodynamic therapy (PDT) of cancer. However the application of ICG-mediated PDT is both intrinsically and physiologically limited. Here we report a combination of ICG-PDT with a chemotherapy drug etoposide (VP-16), aiming to enhance the anticancer efficacy, to circumvent limitations of PDT using ICG, and to reduce side effects of VP-16. We found in controlled in vitro cell-based assays that this combination is effective in killing non-small-cell lung cancer cells (NSCLC, A549 cell line)...
June 5, 2017: Cancers
https://www.readbyqxmd.com/read/28574922/severe-complicated-neutropenia-in-two-patients-with-metastatic-non-small-cell-lung-cancer-treated-with-nivolumab
#7
Ilit Turgeman, Mira Wollner, Gamal Hassoun, Lilach Bonstein, Gil Bar-Sela
Checkpoint inhibitors effectively enhance the natural immune response against cancer, but they are also known to induce a unique spectrum of immune-related adverse events. Here, we report the first case of isolated neutropenia subsequent to nivolumab therapy. Prominent activated T-cells were found in the patient's serum and bone marrow alongside evidence of maturational defects in neutrophil precursors. Antineutrophil antibodies were not detected despite reliable testing techniques. A T-cell-mediated response is probable, consistent with the established mechanism for the development of other immune-related toxicities...
June 1, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28551359/previous-radiotherapy-and-the-clinical-activity-and-toxicity-of-pembrolizumab-in-the-treatment-of-non-small-cell-lung-cancer-a-secondary-analysis-of-the-keynote-001-phase-1-trial
#8
Narek Shaverdian, Aaron E Lisberg, Krikor Bornazyan, Darlene Veruttipong, Jonathan W Goldman, Silvia C Formenti, Edward B Garon, Percy Lee
BACKGROUND: Preclinical studies have found radiotherapy enhances antitumour immune responses. We aimed to assess disease control and pulmonary toxicity in patients who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembrolizumab. METHODS: We assessed patients with advanced NSCLC treated on the phase 1 KEYNOTE-001 trial at a single institution (University of California, Los Angeles, CA, USA). Patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 1 or less, had adequate organ function, and no history of pneumonitis...
May 24, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28542137/dt-13-synergistically-enhanced-vinorelbine-mediated-mitotic-arrest-through-inhibition-of-foxm1-bicd2-axis-in-non-small-cell-lung-cancer-cells
#9
Hongyang Li, Li Sun, Hang Li, Xiaodan Lv, Herve Semukunzi, Ruiming Li, Jun Yu, Shengtao Yuan, Sensen Lin
Non-small-cell lung cancer (NSCLC) is the most commonly diagnosed malignant disease with the leading cause of cancer-related death. Combination treatment remains the major strategy in the clinical therapy of NSCLC. Vinorelbine (NVB), a semi-synthetic vinca alkaloid, is used for advanced and metastatic NSCLC by destabilizing microtubule formation to induce mitotic arrest and cell death. However, the side effect of NVB heavily affected its effectiveness in clinical therapy. Hence, it is of great significance to develop new agents to synergize with NVB and decrease the adverse effect...
May 25, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28534969/the-cdc2-cdk1-inhibitor-purvalanol-a-enhances-the-cytotoxic-effects-of-taxol-through-op18-stathmin-in-non-small-cell-lung-cancer-cells-in%C3%A2-vitro
#10
Xian Chen, Ying Liao, Dan Long, Ting Yu, Fang Shen, Xuechi Lin
Purvalanol A is a highly selective inhibitor of Cdc2 [also known as cyclin-dependent kinase 1 (CDK1)]. Taxol is an anti-tumor chemotherapeutic drug which is widely used clinically. In this study, the CDK1 inhibitor, purvalanol A was applied to explore the relevance of Cdc2 signaling and taxol sensitivity through analyses, such as cellular proliferation and apoptosis assays, ELISA, western blot analysis and immunoprecipitation. We demonstrated that purvalanol A effectively enhanced the taxol-induced apoptosis of NCI-H1299 cells, as well as its inhibitory effects on cellular proliferation and colony formation...
May 15, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28515940/nivolumab-induced-autoimmune-diabetes-mellitus-presenting-as-diabetic-ketoacidosis-in-a-patient-with-metastatic-lung-cancer
#11
James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D Rao, Ranee Mehra, Colleen Veloski
BACKGROUND: Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence of autoimmune side effects associated with these agents, termed immune related adverse events (irAE), is expected to increase. The frequency of significant irAE in ICI treated patients is about 10-20% and early recognition is critical to prevent serious morbidity and even mortality...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28515157/carboxyamidotriazole-synergizes-with-sorafenib-to-combat-non-small-cell-lung-cancer-through-inhibition-of-nanog-and-aggravation-of-apoptosis
#12
Chen Chen, Rui Ju, Jing Shi, Wei Chen, Fangrui Sun, Lei Zhu, Juan Li, Dechang Zhang, Caiying Ye, Lei Guo
Lung cancer is the leading cause of cancer-related deaths in the world. In this study, we investigated the combination of carboxyamidotriazole (CAI) and sorafenib in NSCLC in vitro and in vivo, to test whether CAI enhances the antitumor effects of sorafenib and reduces its side effects. The combination index (CI) showed that co-administration of CAI and sorafenib synergistically inhibited the proliferation of NSCLC cells (Lewis lung carcinoma, A549, NCI-H1975). The cell death led by the treatment of combination drugs was attributed to apoptosis which was accompanied with activation of caspase 3 and poly ADP-ribose polymerase...
May 17, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28512504/a-case-report-of-drug-induced-myopathy-involving-extraocular-muscles-after-combination-therapy-with-tremelimumab-and-durvalumab-for-non-small-cell-lung-cancer
#13
William Carrera, Brandon J Baartman, Gregory Kosmorsky
Recently developed anti-tumour therapies targeting immune checkpoints include tremelimumab and durvalumab. These agents have incompletely characterised side effect profiles. The authors report a 68-year-old man treated for non-small cell lung cancer (NSCLC) with a combination of tremelimumab and durvalumab. After treatment he developed diplopia, ptosis, fatigue, weakness, and an inflammatory myopathy affecting the extraocular muscles requiring hospitalisation. Electromyography (EMG) testing and muscle biopsy suggested inflammatory myopathy without sign of myasthenia...
June 2017: Neuro-ophthalmology
https://www.readbyqxmd.com/read/28506589/the-relationship-between-dosimetric-factors-side-effects-and-survival-in-patients-with-non-small-cell-lung-cancer-treated-with-definitive-radiotherapy
#14
Dilruba Okumus, Sureyya Sarihan, Sema Gozcu, Deniz Sigirli
The patients with non-small cell lung cancer (NSCLC) treated with definitive conformal radiotherapy (RT) were evaluated in terms of side effects and survival. Normal tissue complication probability (NTCP) was calculated for 68 patients treated between 2009 and 2012. Clinical and dosimetric factors were analyzed. The median dose of 63 Gy (range: 54 to 70 Gy) was given with conformal RT with blocks (n = 37), 3-dimensional conformal RT (3DCRT) (n = 11), or intensity-modulated RT (IMRT) (n = 20)...
May 12, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28503645/immune-checkpoint-inhibitors-an-innovation-in-immunotherapy-for-the-treatment-and-management-of-patients-with-cancer
#15
REVIEW
Jennifer Dine, RuthAnn Gordon, Yelena Shames, Mary Kate Kasler, Margaret Barton-Burke
Cancer survival rates are generally increasing in the United States. These trends have been partially attributed to improvement in therapeutic strategies. Cancer immunotherapy is an example of one of the newer strategies used to fight cancer, which primes or activates the immune system to produce antitumor effects. The first half of this review paper concisely describes the cell mechanisms that control antitumor immunity and the major immunotherapeutic strategies developed to target these mechanisms. The second half of the review discusses in greater depth immune checkpoint inhibitors that have recently demonstrated tremendous promise for the treatment of diverse solid tumor types, including melanoma, non-small cell lung cancer, and others...
April 2017: Asia-Pacific Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28491851/pemetrexed-induced-acute-kidney-failure-following-irreversible-renal-damage-two-case-reports-and-literature-review
#16
Tito Zattera, Francesco Londrino, Matteo Trezzi, Roberto Palumbo, Antonio Granata, Paola Tatangelo, Valentina Corbani, Valeria Falqui, Nadia Chiappini, Lisa Mathiasen, Marco Cavallini, Davide Rolla
BACKGROUND: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent with a demonstrated broad-spectrum activity in several types of human cancers, including non-small cell lung cancer (NSCLC) and mesothelioma. Major side effects include dose-limiting hematologic toxicities. PEM nephrotoxicity is well known; however, its frequency is considered to be low. CASE PRESENTATION: Here we report two cases of acute kidney injury (AKI) related to PEM administration (500 mg/m2) in patients with NSCLC...
March 2017: Journal of Nephropathology
https://www.readbyqxmd.com/read/28490892/the-effectiveness-of-egfr-tkis-against-brain-metastases-in-egfr-mutation-positive-non-small-cell-lung-cancer
#17
Hao Bai, Liwen Xiong, Baohui Han
Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and few available therapeutic options. This retrospective study aims to evaluate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) against brain metastases from NSCLC harboring activating EGFR mutation. A total of 148 patients with brain metastases from EGFR mutation-positive NSCLC were analyzed retrospectively. The patients were orally given gefitinib (250 mg) or erlotinib (150 mg) once a day until intracranial disease progression, death, or intolerable side effects...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28481816/changes-in-and-determinants-of-quality-of-life-in-patients-with-advanced-non-small-cell-lung-cancer-undergoing-initial-chemotherapy
#18
Yu-Lee Dai, Cheng-Ta Yang, Kang-Hua Chen, Siew-Tzuh Tang
BACKGROUND: Few studies have evaluated completely the changes in quality of life (QOL) that occur from pretreatment through the first four consecutive cycles of chemotherapy or determined its determinants in patients with advanced non-small-cell lung cancer (NSCLC). PURPOSE: The aim of this study was to explore the changes to and determinants of QOL in patients with advanced NSCLC under initial chemotherapy from pretreatment through Cycle 4 of chemotherapy. METHODS: The QOL of 139 patients with advanced NSCLC was assessed from prechemotherapy through Cycle 4 of chemotherapy...
June 2017: Journal of Nursing Research: JNR
https://www.readbyqxmd.com/read/28480778/ptd-modified-paclitaxel-anti-resistant-liposomes-for-treatment-of-drug-resistant-non-small-cell-lung-cancer
#19
Rui-Jun Ju, Lan Cheng, Yao Xiao, Xin Wang, Cui-Qing Li, Xiao-Ming Peng, Xue-Tao Li
CONTEXT: Non-small cell lung carcinoma (NSCLC) is a type of epithelial lung cancer that accounts for approximately 80-85% of lung carcinoma cases. Chemotherapy for the NSCLC is unsatisfactory due to multidrug resistance, nonselectively distributions and the accompanying side effects. OBJECTIVE: The objective of this study was to develop a kind of PTD modified paclitaxel anti-resistant liposomes to overcome these chemotherapy limitations. METHOD: The studies were performed on LLT cells and resistant LLT cells in vitro and on NSCLC xenograft mice in vivo, respectively...
May 24, 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/28475414/characterization-and-antitumor-efficacy-of-poly-l-lactid-acid-based-etoposide-loaded-implants
#20
Li Gao, Chuanqi Xie, Yuzhi Du, Xiaodong Wang, Erkang Xuan, Xiuxiu Liu, Yang Zhao, Jianjian Xu, Lan Luo
Etoposide is widely used in the chemotherapy of a variety of malignancies. But the strong lipophilicity, poor bioavailability, and severe side effects of etoposide limit its clinical application. The aim of this study was to develop sustained-release etoposide-loaded implants and evaluate antitumor activity of the implants after intratumoral implantation. We prepared the implants containing etoposide, poly(L-lactid acid) and polyethylene glycol 4000 by the direct compression method. The implants were characterized regarding drug-excipient compatibility, content uniformity, morphology, sterility, in vitro, and in vivo release profiles...
November 2017: Drug Delivery
keyword
keyword
3577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"